Friday, February 26, 2021 1:10:01 PM
kgromax,
Please explain your statement that the "endpoint formula" has changed.
The endpoints of the trial did not change. For those who have not followed the leronlimab trials (available here,https://www.clinicaltrials.gov/ct2/show/NCT04343651?term=leronlimab&draw=2&rank=4 with history of changes available at the bottom of each trial's page), I have copied the history of changes (side-by-side), with additions in green and deletions in red.
Careful observers will notice two things. One, that I only included the primary and first 5 secondary outcome criteria. Two, that there are no changes.
I am attempting to spare our careful readers having to looks at three pages of UNCHANGED clinical trial endpoints
The statement made was that
I understand that mathematics is a field of constant discovery, but I doubt that the basics of statistical analysis and calculation of endpoint significance has changed mid-trial.
Is there another explanation I am missing?
Math is unchanged.
Trial endpoints are unchanged.
Whataboutdat?!
Please explain your statement that the "endpoint formula" has changed.
The endpoints of the trial did not change. For those who have not followed the leronlimab trials (available here,https://www.clinicaltrials.gov/ct2/show/NCT04343651?term=leronlimab&draw=2&rank=4 with history of changes available at the bottom of each trial's page), I have copied the history of changes (side-by-side), with additions in green and deletions in red.
Careful observers will notice two things. One, that I only included the primary and first 5 secondary outcome criteria. Two, that there are no changes.
I am attempting to spare our careful readers having to looks at three pages of UNCHANGED clinical trial endpoints
The statement made was that
endpoint formula here has been changed ex-post
I understand that mathematics is a field of constant discovery, but I doubt that the basics of statistical analysis and calculation of endpoint significance has changed mid-trial.
Is there another explanation I am missing?
Math is unchanged.
Trial endpoints are unchanged.
Whataboutdat?!
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
